GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pulmonx Corp (NAS:LUNG) » Definitions » Other Current Assets

Pulmonx (Pulmonx) Other Current Assets : $3.40 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Pulmonx Other Current Assets?

Pulmonx's other current assets for the quarter that ended in Mar. 2024 was $3.40 Mil.

Pulmonx's quarterly other current assets declined from Sep. 2023 ($3.83 Mil) to Dec. 2023 ($3.56 Mil) and declined from Dec. 2023 ($3.56 Mil) to Mar. 2024 ($3.40Mil).

Pulmonx's annual other current assets declined from Dec. 2021 ($4.75 Mil) to Dec. 2022 ($3.97 Mil) declined from Dec. 2022 ($3.97 Mil) to Dec. 2023 ($3.56 Mil).


Pulmonx Other Current Assets Historical Data

The historical data trend for Pulmonx's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pulmonx Other Current Assets Chart

Pulmonx Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Current Assets
Get a 7-Day Free Trial 1.21 3.12 4.75 3.97 3.56

Pulmonx Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.03 3.81 3.83 3.56 3.40

Pulmonx Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.


Pulmonx Other Current Assets Related Terms

Thank you for viewing the detailed overview of Pulmonx's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Pulmonx (Pulmonx) Business Description

Traded in Other Exchanges
Address
700 Chesapeake Drive, Redwood, CA, USA, 94063
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). the company's solutions comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the U.S. and international markets.
Executives
French Glendon E. Iii director, officer: President and CEO 700 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Geoffrey Beran Rose officer: Chief Commercial Officer 5124 ROCKWOOD PARKWAY NW, WASHINGTON DC 20016
John Mckune officer: Interim CFO 46668 CRAWFORD CT., FREMONT CA 94539
David Aaron Lehman officer: General Counsel C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Derrick Sung officer: Chief Financial Officer C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 380, SAN FRANCISCO CA 94103
Alissa Hsu Lynch director 700 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Richard M Ferrari director 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Tiffany Sullivan director 700 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Boston Scientific Corp 10 percent owner 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Daniel P Florin director 56 E. BELL DRIVE, WARSAW IN 46581
Mead Dana G Jr. director 2750 SAND HILL ROAD, MENLO PARK CA 94025
Thomas William Burns director C/O GLAUKOS CORPORATION,, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Georgia Melenikiotou director C/O INSPIRE MEDICAL SYSTEMS, INC., 5500 WAYZATA BOULEVARD, SUITE 1600, GOLDEN VALLEY MN 55416
Staffan Lindstrand director C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51